Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00712322 · ClinicalTrials.gov registry record · Phase 2
A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity
A Phase 2 study, sponsored by Warner Chilcott.
- Terminated
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT00712322 is a Phase 2 study that was terminated before completion, run by Warner Chilcott. The registered enrollment target is 35 participants.
The verdict
NCT00712322, a Phase 2 study, was terminated before completion, sponsored by Warner Chilcott.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
This study will evaluate the pharmacodynamics and pharmacokinetics of darifenacin liquid oral suspension in children, ages 2-15 years, with neurogenic detrusor overactivity. The results will support a benefit-risk based dosage recommendation for phase IIIa clinical trials.
Interventions
- DRUG Darifenacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2008-10-07 |
| Est. Completion | 2013-05-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00712322
The ClinicalTrials.gov registry entry for NCT00712322 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Warner Chilcott, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Darifenacin is the first listed.
NCT00712322 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00712322 about?
NCT00712322 is a clinical study titled "A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity". This study will evaluate the pharmacodynamics and pharmacokinetics of darifenacin liquid oral suspension in children, ages 2-15 years, with neurogenic detrusor overactivity. The results will support a benefit-risk based dosage recommendation for phase IIIa clinical trials.
What is the current status of trial NCT00712322?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2008-10-07. Estimated completion is 2013-05-23.
What interventions are being tested in trial NCT00712322?
The interventions under investigation include: Darifenacin (DRUG).
Who is sponsoring clinical trial NCT00712322?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.